Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / CMMB - Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases

CMMB - Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases

Chemomab Therapeutics Ltd.
  • Chemomab Therapeutics is advancing a first-in-class anti-CCL24 mAb targeting PSC, SSc, and NASH.
  • Lead candidate CM-101 has orphan drug designation by both the FDA and the EMA in its primary indications of PSC and SSc.
  • The company has a cash runway through mid-2023 and has multiple upcoming catalysts.

For further details see:

Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases
Stock Information
Company Name: Chemomab Therapeutics Ltd.
Stock Symbol: CMMB
Market: NASDAQ
Website: chemomab.com
Menu
CMMB CMMB Quote CMMB Short CMMB News CMMB Articles CMMB Message Board
Get CMMB Alerts

News, Short Squeeze, Breakout and More Instantly...